Ghrelin: A new treatment for non-alcoholic fatty liver disease?

Endocrine

Volumn 43, Issue 2, 2013, Pages 247-248

  Delhanty, Patric J D ^a   Van Der Lely, Aart J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DES ACYL GHRELIN; GHRELIN; OBESTATIN; RELEASING FACTOR; UNCLASSIFIED DRUG;

DES ACYL GHRELIN GENE; DISEASE COURSE; EDITORIAL; FOOD INTAKE; GENE; GENE EXPRESSION; GENE PRODUCT; GHRELIN GENE; HUMAN; INCIDENCE; INSULIN RESISTANCE; MOLECULAR PATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESTATIN GENE; PATIENT ASSESSMENT; PRIORITY JOURNAL; PUBLICATION; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION;

EID: 84879553563     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9800-2     Document Type: Editorial

References (11)

1. J.H. Yan Li, L. Lake, C. Xuehui, P.Hua, C. Meng, Z. Qinggui, Administration of ghrelin improves inflammation, oxidative stress, and apoptosis during and after non-alcoholic fatty liver disease development. Endocrine. (2012). doi: 10.1007/s12020-012-9761-5
2. S.E. Mahady, J. George, Management of nonalcoholic steatohepatitis: an evidence-based approach. Clin. Liver Dis. 16, 631-645 (2012)
3. M. Heuer, G.M. Kaiser, A. Kahraman, M. Banysch, F.H. Saner, Z. Mathe, G. Gerken, A. Paul, A. Canbay, J.W. Treckmann, Liver transplantation in nonalcoholic steatohepatitis is associated with high mortality and post-transplant complications: a single-center experience. Digestion 86, 107-113 (2012)
4. T. Takamura, H. Misu, T. Ota, S. Kaneko, Fatty liver as a consequence and cause of insulin resistance: lessons from type 2 diabetic liver [Review]. Endocr. J. (2012)
5. N.J. de Wit, L.A. Afman, M. Mensink M. Muller, Phenotyping the effect of diet on non-alcoholic fatty liver disease. J. Hepatol. (2012)
6. P.J. Delhanty, S.J. Neggers, A.J. Van der Lely, Ghrelin: the differences between acyl- and des-acyl ghrelin. Eur. J. Endocrinol. (2012)
7. M. Estep, M. Abawi, M. Jarrar, L. Wang, M. Stepanova, H. Elariny, A. Moazez, Z. Goodman, V. Chandhoke, A. Baranova, Z.M. Younossi, Association of obestatin, ghrelin, and inflammatory cytokines in obese patients with non-alcoholic fatty liver disease. Obes. Surg. 21, 1750-1757 (2011)
8. Y. Okamatsu, K. Matsuda, I. Hiramoto, H. Tani, K. Kimura, Y. Yada, T. Kakuma, S. Higuchi, M. Kojima, T. Matsuishi, Ghrelin and leptin modulate immunity and liver function in overweight children. Pediatr. Int. 51, 9-13 (2009)
9. Y. Gutierrez-Grobe, I. Villalobos-Blasquez, K. Sanchez-Lara, A.R. Villa, G. Ponciano-Rodriguez, M.H. Ramos, N.C. Chavez-Tapia, M. Uribe, N. Mendez-Sanchez, High ghrelin and obestatin levels and low risk of developing fatty liver. Ann. Hepatol. 9, 52-57 (2010)
10. S. Aydin, Is it appropriate to study blood ghrelin and obestatin in non-alcoholic fatty liver disease (NAFLD) without using protease inhibitors? Ann. Hepatol. 11, 145-146 (2012)
11. P.J. Delhanty, Y. Sun, J.A. Visser, A. van Kerkwijk, M. Huisman, W.F. van Ijcken, S. Swagemakers, R.G. Smith, A.P. Themmen, A.J. van der Lely, Unacylated ghrelin rapidly modulates lipogenic and insulin signaling pathway gene expression in metabolically active tissues of GHSR deleted mice. PLoS ONE 5, e11749 (2010)